BioStock: CombiGene’s CEO on the terminated collaboration with Spark

Over the weekend, CombiGene received the news that Spark Therapeutics has terminated the collaboration agreement for the epilepsy project CG01. BioStock reached out to CEO Peter Ekolind for a comment on the unexpected announcement and what prompted the decision.

Read the interview with Peter Ekolind at biostock.se:

https://www.biostock.se/en/2023/10/combigenes-ceo-on-the-terminated-collaboration-with-spark/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/